UroGen Pharma is expected to report Q3 2026 revenue of approximately $90.25 million and a consensus EPS of $0.11, with the stock currently trading near $33.59 against an average analyst price target of $60.00.
Investors are primarily focused on the commercial ramp of ZUSDURI (UGN-102), which is serving as the company's core growth engine following its 2025 FDA approval for bladder cancer treatment.
The company achieved strong momentum in the prior quarter, with ZUSDURI sales surging 73% sequentially to $50.4 million. This commercial success is bolstered by stable adoption of its legacy product, Jelmyto, and the recent regulatory progression of UGN-103, which received FDA acceptance for its New Drug Application in October 2026.